Moreover, DPP4 levels were markedly increased in the subcutaneous tumor tissues post‐treatment, which simulated the minimal residual disease (MRD), as well as in the orthotopic tumors receiving osimertinib and residual lesions from patients after EGFR‐TKIs treatment. The gene discussed is DPP4; the disease is neoplasm.